InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Carboat post# 271004

Saturday, 08/27/2016 7:38:32 AM

Saturday, August 27, 2016 7:38:32 AM

Post# of 345787
Those may be about the same odds that a small biotech would have under their control the targeting of a ligand (PS) that seemed to only be involved in cell death but was actually the link to allow the full restoral of an immune response ....

Imagine that out of all the Billions in profits of Big Pharma, that not a one of them were able to discover PS Targeting...and they don't own it.... Yet

Those are about also the odd that PS Targeting will not be bought out. You see the conflict now?

Think Big and Think Bavi

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News